Quinidine hydrochloride monohydrate

Name: Quinidine hydrochloride monohydrate
Brand: MedChemExpress
SKU: HY-B1302
Rating: 5.0 (24 reviews)

Cat. No.: HY-B1302 Purity: 99.97%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Quinidine hydrochloride monohydrate is an orally active antiarrhythmic agent. Quinidine hydrochloride monohydrate reduces the expression level of P-gp, inhibits P-gp-mediated efflux, increases the intracellular accumulation of P-gp substrates, induces PARP cleavage and Caspase-3 activation, and elevates the proportion of Apoptotic cells at the sub-G1 phase. Quinidine hydrochloride monohydrate exerts sustained block and open-channel block effects on I_K(f). Quinidine hydrochloride monohydrate alters the urinary metabolic ratio of Amphetamine, modulates the Pentylenetetrazol-induced seizure threshold, and regulates the anticonvulsant effect of Dextromethorphan. Quinidine hydrochloride monohydrate can be used in studies related to uterine sarcoma and seizures.

For research use only. We do not sell to patients.

CAS No. : 6151-40-2

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 24 publication(s) in Google Scholar

Other Forms of Quinidine hydrochloride monohydrate:

Quinidine (15% dihydroquinidine) In-stock
Quinidine sulfate Get quote
Quinidine sulfate dihydrate Get quote
Quinidine polygalacturonate Get quote
Quinidine gluconic acid Get quote
Quinidine hydrochloride monohydrate (Standard) Get quote

24 Publications Citing Use of MCE Quinidine hydrochloride monohydrate

Flow Cytometry

Bio/Physico-chemical Assay

RT-PCR

: Quinidine hydrochloride monohydrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 19:e05666. [Abstract]; Quinidine rescued [Mg^2⁺]_i levels in LPS‐treated or TRPM7‐silenced DPSCs and SCAP.

: Quinidine hydrochloride monohydrate purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2021 Aug 15:416:125764. [Abstract]; Effects of CYP enzymes inhibitors on metabolic rates of cyproconazole stereoisomers in the in vitro incubation mixtures with RLMs. The asterisks (*) indicates the significant difference in metabolic rates under inhibition compared to the control.

: Quinidine hydrochloride monohydrate purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Jul 31;11:1038. [Abstract]; Cell cycle relative proteins/genes (CyclinD1, CDK4, P21 and P27) level were assessed in HConFs after Quinidine treatment by western blot.

: Quinidine hydrochloride monohydrate purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Jul 31;11:1038. [Abstract]; Cell cycle relative proteins/genes (CyclinD1, CDK4, P21 and P27) level were assessed in HConFs after Atropine/Quinidine treatment by qRT-PCR.

: Quinidine hydrochloride monohydrate purchased from MedChemExpress. Usage Cited in: Environ Int. 2019 Jun;127:694-703. [Abstract]; CYP2D6 has contributed in the enantioselectivity of IFP and ICPO because the EF value of the KND-supplemented group follows a doseeffect relationship and the difference in the EF values was over 10% relative to the DMSO control group.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PARP Isoform Specific Products:

View All Isoforms

PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

View All Caspase Isoform Specific Products:

View All Isoforms

Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2]^[3]^[4]

Caspase 3

Cellular Effect

Cell Line	Type	Value	Description	References
Vero C1008	CC₅₀	> 40 μM Compound: Quinidine hydrochloride monohydrate	Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm) Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm)	10.1101/2020.04.03.023846
Vero C1008	EC₅₀	5.11 μM Compound: Quinidine hydrochloride monohydrate	Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days	10.1101/2020.04.03.023846

In Vitro

Quinidine (10 μM; 24 h) hydrochloride monohydrate potentiates Paclitaxel (HY-B0015)-induced cytotoxicity in P-gp-positive MES-SA/DX5 uterine sarcoma cells (reducing paclitaxel IC₅₀ to 80.56 nM) but does not alter paclitaxel cytotoxicity in P-gp-negative MES-SA uterine sarcoma cells^[1].
Quinidine (10 μM; 24 h) hydrochloride monohydrate significantly increases the sub-G1 apoptotic portion in paclitaxel-treated P-gp-positive MES-SA/DX5 uterine sarcoma cells, enhancing paclitaxel-induced apoptosis^[1].
Quinidine inhibits the in vitro metabolism of Debrisoquine in rat liver microsomes, with lower potency than observed in human liver microsomes^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	P-gp-negative MES-SA uterine sarcoma cells, P-gp-positive MES-SA/DX5 uterine sarcoma cells
Concentration:	10 μM
Incubation Time:	24 h
Result:	Did not significantly alter the cytotoxicity of paclitaxel in MES-SA cells, with paclitaxel IC₅₀ remaining comparable to paclitaxel alone (19 nM vs. 18 nM). Strongly potentiated paclitaxel-induced cytotoxicity in MES-SA/DX5 cells, reducing the IC₅₀ of paclitaxel from 13851 nM to 81 nM. Showed no significant cytotoxicity up to 100 μM in either cell line.\nShowed concentration-dependent cytotoxicity with docetaxel against MES-SA cells. Enhanced docetaxel-induced cytotoxicity in MES-SA/DX5 cells more potently than hydrocinchonine, alongside cinchonine. Showed no significant cytotoxicity up to 100 μM in either cell line.

Cell Cycle Analysis^[1]

Cell Line:	P-gp-positive MES-SA/DX5 uterine sarcoma cells (paclitaxel-treated)
Concentration:	10 μM
Incubation Time:	24 h
Result:	Significantly increased the sub-G1 apoptotic portion (G₀ = 27.19) in paclitaxel-treated MES-SA/DX5 cells, whereas paclitaxel alone induced minimal sub-G1 accumulation (G₀ = 0.05).

In Vivo

Quinidine (80 mg/kg; p.o.; single administration) hydrochloride monohydrate potently inhibits amphetamine ring hydroxylation in male Lewis rats, reducing the excretion of p-hydroxyamphetamine to 7.2% and 24.1% of the control group levels at 24 h and 48 h, respectively, while increasing the late-phase excretion of amphetamine to 542% of the control group level^[3].
Quinidine (10-30 mg/kg; intraperitoneal injection; single administration) hydrochloride monohydrate significantly elevates the threshold of pentylenetetrazol-induced tonic convulsions in male NMRI mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Lewis (male, 175-225 g)^[3]
Dosage:	80 mg/kg
Administration:	p.o.; single dose
Result:	Reduced urinary excretion of p-hydroxyamphetamine to 7.2% of vehicle-control levels in the 0-24 h collection period. Reduced urinary excretion of p-hydroxyamphetamine to 24.1% of vehicle-control levels in the 24-48 h collection period. Increased amphetamine excretion to 542% of control levels in the 24-48 h period. Excreted an average of 0.40 μmol p-hydroxyamphetamine and 7.80 μmol amphetamine in the 0-24 h period. Excreted an average of 3.60 μmol amphetamine and a significantly reduced amount of p-hydroxyamphetamine relative to controls in the 24-48 h period. Achieved total combined excretion of amphetamine and p-hydroxyamphetamine over 48 h equal to 79.7% of the administered dose, which was not significantly different from control groups.

Animal Model:	NMRI (male, 5-6 weeks old, 25-30 g)^[4]
Dosage:	10 mg/kg; 20 mg/kg; 30 mg/kg
Administration:	i.p.; single dose
Result:	Did not alter the pentylenetetrazole threshold dose for onset of myoclonic twitch. Significantly increased the pentylenetetrazole threshold dose for onset of tonic hind limb extension compared to saline-treated controls (p < 0.05).

Molecular Weight

378.89

Formula

C₂₀H₂₇ClN₂O₃

CAS No.

6151-40-2

Appearance

Solid

Color

White to off-white

SMILES

C=C[C@H]1C[N@](CC[C@H]1C2)[C@@]2([H])[C@@H](O)C3=CC=NC4=CC=C(OC)C=C34.[H]Cl.[H]O[H]

Structure Classification

Others

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (263.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2.5 mg/mL (6.60 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6393 mL	13.1964 mL	26.3929 mL
5 mM	0.5279 mL	2.6393 mL	5.2786 mL
10 mM	0.2639 mL	1.3196 mL	2.6393 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.60 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.97%

Select Batch:

Data Sheet (288 KB) SDS (393 KB)

COA (255 KB) HNMR (293 KB) RP-HPLC (246 KB) MS (68 KB)

Handling Instructions (2659 KB)

References

[1]. Lee SY, et al. Hydrocinchonine, cinchonine, and quinidine potentiate paclitaxel-induced cytotoxicity and apoptosis via multidrug resistance reversal in MES-SA/DX5 uterine sarcoma cells. Environ Toxicol. 2011 Aug;26(4):424-31. [Content Brief]

[2]. Kehl SJ, et al. Quinidine-induced inhibition of the fast transient outward K+ current in rat melanotrophs. Br J Pharmacol. 1991;103(3):1807-1813. [Content Brief]

[3]. Moody DE, et al. Quinidine inhibits in vivo metabolism of amphetamine in rats: impact upon correlation between GC/MS and immunoassay findings in rat urine. J Anal Toxicol. 1990;14(5):311-317. [Content Brief]

[4]. Jamali H, et al. Effect of dextromethorphan/quinidine on pentylenetetrazole- induced clonic and tonic seizure thresholds in mice. Neurosci Lett. 2020;729:134988. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	2.6393 mL	13.1964 mL	26.3929 mL	65.9822 mL
H₂O / DMSO	5 mM	0.5279 mL	2.6393 mL	5.2786 mL	13.1964 mL
DMSO	10 mM	0.2639 mL	1.3196 mL	2.6393 mL	6.5982 mL
	15 mM	0.1760 mL	0.8798 mL	1.7595 mL	4.3988 mL
	20 mM	0.1320 mL	0.6598 mL	1.3196 mL	3.2991 mL
	25 mM	0.1056 mL	0.5279 mL	1.0557 mL	2.6393 mL
	30 mM	0.0880 mL	0.4399 mL	0.8798 mL	2.1994 mL
	40 mM	0.0660 mL	0.3299 mL	0.6598 mL	1.6496 mL
	50 mM	0.0528 mL	0.2639 mL	0.5279 mL	1.3196 mL
	60 mM	0.0440 mL	0.2199 mL	0.4399 mL	1.0997 mL
	80 mM	0.0330 mL	0.1650 mL	0.3299 mL	0.8248 mL
	100 mM	0.0264 mL	0.1320 mL	0.2639 mL	0.6598 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.